0001420800-25-000032
SEC filingEnovis revenue up 7.5% in Q2 2025 to $564.5M, with Recon segment driving growth; Adjusted EBITDA margin steady at 17.2%.
Enovis reported Q2 2025 net sales of $564.5 million, up 7.5% year-over-year, driven by existing business growth of 5.2% and favorable foreign currency translation of 2.0%, partially offset by holiday timing. Gross profit rose 15.9% to $334.7 million, with gross margin expanding 430 bps to 59.3% due to lower inventory fair value step-up amortization and supply chain productivity. Operating loss improved to $(16.8) million from $(44.3) million, reflecting higher gross profit and lower strategic transaction costs. Net loss from continuing operations was $(36.5) million versus $(18.4) million last year, primarily due to a $33.5 million mark-to-market gain on contingent shares in the prior year and the $10.0 million purchase of royalty interest. Adjusted EBITDA increased to $97.2 million, with margin steady at 17.2%.
Prevention & Recovery: Net sales grew 4.6% to $290.6 million, driven by existing business volume and favorable FX. Gross margin improved 220 bps to 54.8% on better product mix and productivity. Operating income rose to $9.3 million (3.2% margin) from $2.5 million, aided by lower restructuring and MDR costs. Adjusted EBITDA margin increased to 16.1% from 14.8%.
Reconstructive: Net sales increased 10.7% to $274.0 million, with existing business up 8% ex-FX. Gross margin surged 640 bps to 64.1%, benefiting from a $17.9 million reduction in inventory step-up. Operating loss narrowed to $(26.1) million from $(46.8) million, despite a $10.0 million royalty charge, due to higher gross profit and lower integration costs. Adjusted EBITDA margin decreased slightly to 18.4% from 19.8%, as royalty charge offset operational leverage.
Management highlighted ongoing strategic acquisitions (seven in H1 2025 for $35.4 million) and the completed Lima acquisition integration as key growth drivers. The company expects to fund operations through cash flows, revolver availability ($325 million), and debt capacity. No formal quantitative guidance was provided, but the MD&A noted that existing business momentum, supply chain productivity, and cost control are expected to support margin improvement. The purchase of royalty interest and continued investment in R&D for Recon's surgical productivity solutions signal a focus on innovation. Liquidity is deemed adequate for the next twelve months.
As of July 4, 2025, Enovis held $44.1M in cash and equivalents, with total debt of $1.39B. The company maintains a $900M revolving credit facility, with $325M undrawn. Net debt increased $64M during the six-month period primarily due to acquisitions and capex. The balance sheet remains leveraged, with debt-to-equity of 0.54.
The Notes disclose a $56.5M purchase of royalty interest liability, representing the buyout of future royalty payments on legacy reconstructive products, payable over nine years. Additionally, contingent consideration liabilities of $19.0M (Level 3) and $52.3M in derivative liabilities (forward currency contracts) are recorded. The company has $50.1M in outstanding letters of credit and surety bonds.
Enovis did not repurchase any shares during the period; $100M remains authorized. No dividends were paid. Debt activity included $127M in revolver borrowings and $10M term loan repayment, with net debt increase of $64M. Capital expenditures totaled $87.6M (7.8% of sales), primarily in the Recon segment ($73.3M). The company completed seven bolt-on acquisitions for $37M in cash plus contingent consideration.
The Prevention & Recovery segment generated $563.2M in sales (+4.9% YoY) and Adjusted EBITDA of $77.6M. U.S. Bracing & Support accounted for $235.9M, U.S. Other P&R $137.4M, and International $189.8M. The Reconstructive segment contributed $560.2M (+11.0% YoY) and Adjusted EBITDA of $118.7M, with U.S. at $267.4M and International at $292.9M. The Recon segment’s higher EBITDA reflects stronger margins and scale.
Enovis reported a net loss of $92.3 million for the first half of 2025, yet operating cash flow was positive at $46.2 million. This divergence is driven by significant non-cash charges: depreciation and amortization of $143.0 million, stock-based compensation of $16.1 million, and non-cash interest of $3.2 million. A fair value loss on contingent acquisition shares added $1.8 million, while deferred tax benefits reduced cash flow by $3.7 million. Working capital changes also contributed positively, with a $23.2 million increase in accounts payable and a $32.1 million inflow from other operating assets and liabilities, offset by a $57.3 million inventory build and a $20.8 million rise in receivables.
Capital expenditures of $87.6 million (capex intensity ~190% of operating cash flow) consumed most of the CFO, leaving no free cash flow after capex. However, the company continued acquisition activity with $24.3 million in payments. Financing activities provided net $57.4 million, driven by $127 million in revolving credit draws against $55 million in repayments and $10 million in term loan repayments. There were no share repurchases or dividends.
Overall, cash flow quality is moderate: while CFO turned positive, heavy capex and acquisition spending necessitate external financing. The significant working capital outflows for inventories warrant monitoring for future cash conversion.